MRSH CapEx decreased by 41.0% to $62.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.7%, from $55.00M to $62.00M. Over 4 years (FY 2021 to FY 2025), CapEx shows a downward trend with a -8.0% CAGR.
An increase often signals growth initiatives and capacity expansion, while a decrease may suggest cost-cutting or a shift toward asset-light strategies.
This metric measures the cash outflows used to acquire, upgrade, and maintain physical assets such as property, building...
Commonly compared as a percentage of revenue; capital-intensive firms like Abbott require consistent investment to remain competitive in medical technology.
capital_expenditures| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $82.00M | $117.00M | $138.00M | $122.00M | $117.00M | $128.00M | $103.00M | $84.00M | $101.00M | $111.00M | $120.00M | $87.00M | $80.00M | $73.00M | $76.00M | $55.00M | $59.00M | $72.00M | $105.00M | $62.00M |
| QoQ Change | — | +42.7% | +17.9% | -11.6% | -4.1% | +9.4% | -19.5% | -18.4% | +20.2% | +9.9% | +8.1% | -27.5% | -8.0% | -8.8% | +4.1% | -27.6% | +7.3% | +22.0% | +45.8% | -41.0% |
| YoY Change | — | — | — | — | +42.7% | +9.4% | -25.4% | -31.1% | -13.7% | -13.3% | +16.5% | +3.6% | -20.8% | -34.2% | -36.7% | -36.8% | -26.3% | -1.4% | +38.2% | +12.7% |
| Segment | FY'21 | FY'22 |
|---|---|---|
| Riskand Insurance Services | $214.00M | $283.00M |
| Consulting | $109.00M | $109.00M |
| Total | $406.00M | $470.00M |
All segment values are derived from annual filings.
Consulting, Riskand Insurance Services were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.